Live tape
Top 8, mentions 7d10,776GOOGL2,063 mentions▲ +0.04SNDK1,523 mentions▲ +0.11SPCX1,494 mentions▲ +0.08NBIS1,420 mentions▲ +0.09HTZ1,232 mentions▲ +0.10NVDA1,189 mentions▲ +0.08META1,016 mentions▲ +0.03MSFT839 mentions▲ +0.06

Equity · Healthcare

GRAL

GRAIL, Inc. · NasdaqGS

$73 +1.39% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$80 $50 20 May 17 Jul

The line runs $66 on 20 May through $73 on 17 July, on a scale from $50 to $80. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of GRAL over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $66 on 20 May 2026 through $73 on 17 July 2026.

Market cap $3.3B
52-week range $31.41 – $116
Avg volume 91.6K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

GRAL insider trades

SEC Form 4 · last 90 days · newest reported trade 4 Jun 2026
Open-market buys 0
Open-market sells 1
Net sold $91K
Non-trade filings 9
Date Insider Type Shares Value
04 Jun 2026 Partridge Andrew John Chief Growth Officer Sell 1,491 $91K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
15 Jul 2026 CHASE WILLIAM J Director Award 276 $21K
15 Jul 2026 MIZELL STEVEN Director Award 268 $20K
15 Jul 2026 SUMME GREGORY L Director Award 427 $32K
18 Jun 2026 CHASE WILLIAM J Director Award 5,491 $350K
18 Jun 2026 Krevans Sarah Director Award 5,491 $350K
18 Jun 2026 SUMME GREGORY L Director Award 5,491 $350K
18 Jun 2026 MIZELL STEVEN Director Award 5,491 $350K
03 Jun 2026 Ofman Joshua J. Chief Executive Officer Award 3,154 $193K
01 Jun 2026 Ofman Joshua J. Chief Executive Officer Award 27,901 $1.80M

GRAL reported financials

SEC EDGAR XBRL

GRAL reported revenue of $147.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$408.4M.

Figure Reported Period
Revenue $147.2M 31 Dec 2025 fiscal year
Net income −$408.4M 31 Dec 2025 fiscal year
Diluted EPS −$11.11 31 Dec 2025 fiscal year
Total assets $2.8B 30 Jun 2026 at period end
Total equity $2.5B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

GRAL earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-2.56 $45M
31 Mar 2026 Q1 2026 $-2.29 $41M
31 Dec 2025 FY 2025 $-11.11 $147M
30 Sep 2025 Q3 2025 $-2.46 $36M
30 Jun 2025 Q2 2025 $-3.18 $36M
31 Mar 2025 Q1 2025 $-3.10 $32M
31 Dec 2024 FY 2024 $-63.54 $126M
30 Sep 2024 Q3 2024 $-3.94 $29M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

GRAL institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a GRAL position for the quarter ended 30 Jun 2026 — a combined $305.1M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 4,028,614 $275.0M
AQR Capital Management Trimmed −27.6% shares 211,341 $14.2M
D. E. Shaw & Co. Added +42.3% shares 116,102 $7.9M
GAMCO Investors Held (±25%) −0.1% shares 66,713 $4.6M
Two Sigma Investments Trimmed −57.6% shares 27,425 $1.9M
Renaissance Technologies Trimmed −83.3% shares 9,200 $628K
Man Group Trimmed −85.0% shares 7,659 $523K
Marshall Wace Trimmed −89.6% shares 6,202 $423K
Citadel Advisors Exited
Millennium Management Exited

Source: SEC EDGAR 13F filings

GRAL fails-to-deliver

SEC CNS data

On 24 Jul 2026, 293 shares of GRAL failed to deliver (about $21K).

Settlement date Shares failed Notional % of shares out
24 Jul 2026 293 $21K 0.001%
20 Jul 2026 4,750 $345K 0.011%
17 Jul 2026 155 $11K <0.001%
16 Jul 2026 7 $521 <0.001%

Source: SEC fails-to-deliver (CNS) data